These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 2411125)
1. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases. Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125 [TBL] [Abstract][Full Text] [Related]
2. [Assay of serum elastase 1 in adenocarcinoma of the pancreas: diagnostic value, compared and combined study with serum CEA and CA 19-9]. Charneau J; Douay O; Daver A; Boyer J Gastroenterol Clin Biol; 1988; 12(6-7):548-52. PubMed ID: 3166429 [TBL] [Abstract][Full Text] [Related]
3. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer. Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536 [TBL] [Abstract][Full Text] [Related]
4. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Ozkan H; Kaya M; Cengiz A Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813 [TBL] [Abstract][Full Text] [Related]
5. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction. Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354 [TBL] [Abstract][Full Text] [Related]
6. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA. Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994 [TBL] [Abstract][Full Text] [Related]
7. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases. Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346 [TBL] [Abstract][Full Text] [Related]
8. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer]. Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical staining of pancreatic cancer with CA19-9, KM01, unabsorbed CEA, and absorbed CEA. A comparison with normal pancreas and chronic pancreatitis. Shimizu M; Saitoh Y; Ohyanagi H; Itoh H Arch Pathol Lab Med; 1990 Feb; 114(2):195-200. PubMed ID: 1689141 [TBL] [Abstract][Full Text] [Related]
10. [Serum pancreatic enzymes and enzyme inhibitor as a tumor marker for pancreatic cancer]. Ogawa M Rinsho Byori; 1986 Nov; 34(11):1229-35. PubMed ID: 2434691 [No Abstract] [Full Text] [Related]
11. [The role of CEA, CA 19-9 and TPA in the diagnosis of pancreatic cancer. Evaluation by discriminant analysis]. Basso D; Fabris C; Del Favero G; Panucci A; Piccoli A; Plebani M; Pedrazzoli S; Baccaglini U; Lise M; Burlina A Minerva Med; 1986 Apr; 77(16):613-6. PubMed ID: 3458035 [TBL] [Abstract][Full Text] [Related]
12. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases. Piantino P; Andriulli A; Gindro T; Pecchio F; Masoero G; Cavallini G; Naccarato R; Dobrilla G Am J Gastroenterol; 1986 Jun; 81(6):436-9. PubMed ID: 3458359 [TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma. Lucarotti ME; Habib NA; Kelly SB; Rothnie ND; Nelson O; Lindholm L; Cooper MJ; Wood CB; Williamson RC Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358 [TBL] [Abstract][Full Text] [Related]
14. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer]. Safi F; Büchler M; Schenkluhn B; Beger HG Dtsch Med Wochenschr; 1984 Dec; 109(49):1869-73. PubMed ID: 6209082 [TBL] [Abstract][Full Text] [Related]
15. [CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon]. Klapdor R; Klapdor U; Bahlo M; Dallek M; Kremer B; van Ackeren H; Schreiber HW; Greten H Dtsch Med Wochenschr; 1984 Dec; 109(51-52):1949-54. PubMed ID: 6595110 [TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma. Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397 [TBL] [Abstract][Full Text] [Related]
17. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice. Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731 [TBL] [Abstract][Full Text] [Related]
18. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases]. Czakó L; Takács T; Babarczy E; Dux L; Lonovics J Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648 [TBL] [Abstract][Full Text] [Related]
19. Immunological diagnosis of pancreatic cancer by assaying carcinoembryonic antigen (CEA) in pure pancreatic juice. Nishida K; Yoshikawa T; Kondo M; Thiele HG Hepatogastroenterology; 1980 Dec; 27(6):488-94. PubMed ID: 7203382 [TBL] [Abstract][Full Text] [Related]
20. [Tumor markers of pancreatic cancer]. Takami H; Hishinuma S; Shintoku J; Furuuchi T; Ogata Y; Abe O Gan To Kagaku Ryoho; 1985 Feb; 12(2):212-9. PubMed ID: 3855615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]